This HTML5 document contains 40 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/drugbank/drug/DB08954/identifier/wikipedia/
n10http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n8http://linked.opendata.cz/resource/drugbank/drug/DB08954/identifier/kegg-drug/
n7http://linked.opendata.cz/resource/drugbank/drug/DB08954/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://www.drugs.com/international/
n15http://linked.opendata.cz/resource/atc/
n14http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08954
rdf:type
n3:Drug
n3:description
Ifenprodil is a selective NMDA receptor (glutamate) antagonist.
n3:group
approved withdrawn
owl:sameAs
n10:DB08954
dcterms:title
Ifenprodil
adms:identifier
n6:Ifenprodil n7:DB08954 n8:D08064
n3:salt
n3:synthesisReference
U.S. Patent 3,509,164.
foaf:page
n13:ifenprodil.html
n3:IUPAC-Name
n4:271B5F90-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5F96-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5F95-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5F92-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5F93-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5F94-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5F8E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5F8F-363D-11E5-9242-09173F13E4C5 n4:271B5F8C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5F8D-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n15:C04AX28
n3:H-Bond-Acceptor-Count
n4:271B5F9C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5F9D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5F97-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5F98-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5F9A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5F99-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5F9B-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
23210-56-2
n3:Bioavailability
n4:271B5FA2-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5FA4-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5FA5-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5FA1-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5FA0-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5FA3-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5F91-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5F9E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5F9F-363D-11E5-9242-09173F13E4C5